FDA Current Good Manufacturing Practice for Medical Gases

Medical gases — oxygen, nitrous oxide, nitrogen, carbon dioxide, helium, medical air, and their mixtures — are FDA-regulated drugs. When administered to patients in hospitals, surgical centers, or at home, they must meet the same purity and quality standards as any other drug product: accurately labeled, uncontaminated, of the specified concentration, and manufactured under conditions that prevent mix-ups between gases. 21 CFR Part 213 — Current Good Manufacturing Practice for Medical Gases — establishes the minimum GMP requirements for companies that fill, repackage, or otherwise manufacture medical gases, adapting the general drug GMP framework (21 CFR Parts 210–211) to the unique characteristics of gases: high-pressure cylinders, bulk liquid oxygen tanks, cryogenic handling, and the inherent risk of catastrophic patient harm if gases are switched (nitrogen dispensed as oxygen, for example, causes immediate suffocation).

Legal Authority

• 21 U.S.C. § 351 — FDCA § 501: medical gases are drugs subject to FDCA; a medical gas that fails to meet GMP requirements is adulterated
• 21 U.S.C. § 360ddd et seq. — Medical Gas Safety Act of 2017 (part of the FDA Reauthorization Act of 2017): established dedicated regulatory framework for medical gases; requires medical gas producers to register, comply with medical gas-specific GMP, and meet safety reporting requirements; authorized creation of 21 CFR Part 213
• 21 CFR Part 213 — FDA GMP regulations specifically for medical gases (oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, etc.); parallel to but distinct from 21 CFR Parts 210/211 (pharmaceutical GMP)

Key Mechanics

Medical gases like oxygen, nitrous oxide, and carbon dioxide are regulated as drugs because they are administered to patients for therapeutic purposes. Part 213 establishes cGMP standards specific to the medical gas industry: requirements for bulk gas production (purity testing, storage), cylinder filling (cross-connection prevention, contamination control), labeling (color coding, content identification), and distribution. The most critical safety requirement is contamination prevention: cross-contaminating an oxygen cylinder with another gas could be immediately fatal; Part 213 mandates specific procedures to prevent such errors. Manufacturers must test each cylinder lot for identity and purity before release; records must be maintained for 1 year after expiration date or 2 years after distribution, whichever is longer.

Current Rule (2026)

What This Rule Does

Before Part 213 was finalized in June 2024 (effective December 18, 2025), medical gas manufacturers operated under the general pharmaceutical GMP regulations at 21 CFR Parts 210–211. Because those regulations were written for liquid and solid dosage forms, many of their requirements were difficult to adapt to the cylinder-filling, bulk cryogenic storage, and pipeline distribution infrastructure of medical gas companies. Part 213 creates a gas-specific GMP framework covering all aspects of medical gas manufacturing: facilities design, equipment qualification, quality unit responsibilities, receipt and testing of incoming gas components, production procedures, labeling controls, laboratory testing, and recordkeeping. The central concern throughout is mix-up prevention — avoiding situations where a cylinder filled with nitrogen or carbon dioxide is labeled as, and administered as, oxygen.

Key Provisions

Quality Unit and Personnel

• § 213.22 — Quality unit responsibilities: every medical gas manufacturer must have a quality unit with authority to approve or reject all components, incoming designated gases, in-process materials, labeling, and finished gases; the quality unit may not release a batch for distribution without reviewing production and laboratory records to confirm compliance with specifications; this mirrors the pharmaceutical GMP "Quality Control unit" concept adapted for gas operations

• § 213.25 — Personnel qualifications: all persons engaged in manufacturing, processing, packing, or holding medical gases must have education, training, or experience enabling them to perform their functions; training records are required; because the consequences of a gas mix-up are immediately life-threatening, FDA emphasizes documented competency for personnel who fill cylinders, operate manifolds, and apply labels

Facilities and Equipment

• § 213.42 — Design and construction: facilities must provide adequate space and physical separation to prevent mix-ups between different gas types, between incoming designated gases and finished products, and between components; this typically means color-coded cylinder valve connections (CGA fittings specific to each gas), dedicated manifolds, physical separation of gas storage areas, and visual confirmation checkpoints; the facility design is the first line of defense against catastrophic gas mix-ups

• § 213.63 — Equipment design, size, and location: equipment must be of appropriate design and adequate size for its intended use; cylinder filling equipment (high-pressure pumps, manifolds, flowmeters) must be designed to prevent cross-contamination between gas types; dedicated equipment for oxygen (cleaned and free of hydrocarbon contamination) is required because oxygen + hydrocarbons is a fire/explosion hazard

• § 213.67 — Equipment maintenance and cleaning: written cleaning and maintenance procedures required; for oxygen service equipment, this includes cleaning to oxygen-compatible standards (no hydrocarbon residues); equipment use logs must be maintained

• § 213.68 — Calibration of automatic and electronic equipment: pressure gauges, flowmeters, gas analyzers, and electronic fill equipment must be routinely calibrated and records maintained; calibration traceability to NIST standards is expected

Incoming Gases and Components

• § 213.80 — General requirements: written procedures must cover receipt, identification, storage, handling, sampling, testing, and approval or rejection of all components and incoming designated medical gases

• § 213.82 — Receipt and storage of incoming gases: upon receipt, each shipment of incoming gas must either receive full compendial testing (USP monograph testing for identity, purity, and concentration) or be accompanied by a certificate of analysis from the supplier; the manufacturer must verify the COA and confirm it matches the specification before accepting the gas into manufacturing — COA reliance without verification is insufficient under FDA's current enforcement approach

• § 213.84 — Testing and approval: containers (cylinders, bulk tanks, valves) must be examined for conformance with specifications before use; this includes visual inspection for cylinder condition, valve compatibility, and absence of contamination

• § 213.94 — Containers and closures: medical gas containers must not react with, add to, or absorb gas in ways that alter purity; valve and connection systems (CGA-specific fittings) are the principal closure system for cylinders and must maintain integrity throughout the product's use

Production and Process Controls

• § 213.100 — Written procedures: all production and process control procedures must be in writing, drafted, reviewed, and approved by appropriate organizational units (including the quality unit); deviations must be documented and investigated

• § 213.101 — Charge-in of components: procedures must document the quantity and identity of each incoming gas charged into a production batch; for cylinder filling from a bulk liquid oxygen or nitrogen source, each fill must be documented as to source lot and quantity

• § 213.110 — Sampling and testing of in-process materials: where applicable, in-process identity testing (e.g., oxygen analyzer verification) must be performed before filling cylinders — this is the critical check that confirms the gas being filled is the gas specified on the cylinder label

• § 213.122 — Materials examination for labeling and packaging: labels and packaging must be representative sampled and examined upon receipt; label mix-ups for medical gases (e.g., an oxygen label applied to a nitrogen cylinder) have caused patient deaths and are a central enforcement focus

• § 213.125 — Labeling issuance: labeling operations must be controlled to prevent label mix-ups; reconciliation of labels issued, used, and returned is required; excess labels must be destroyed

• § 213.130 — Packaging and labeling operations: written procedures must include physical or spatial separation from operations on other products, and label examination (including online label verification where automated) before and after labeling

Laboratory Controls

• § 213.160 — General requirements: all laboratory specifications, sampling plans, and test procedures must be formally established and documented; laboratory controls must be followed consistently

• § 213.165 — Testing and release: each batch of medical gas must receive appropriate laboratory testing (identity and concentration at minimum) before release for distribution; no batch may be distributed without quality unit approval based on satisfactory test results; for oxygen, this means confirmatory identity testing by gas chromatography or oxygen analyzer showing ≥ 99.0% O₂ per USP specifications

• § 213.166 — Stability testing: gases marketed under FDA drug applications (NDAs or ANDAs) must conduct stability testing under ICH or equivalent protocols; expiration dates must be based on stability data; most commodity medical gases (oxygen, nitrogen, nitrous oxide) do not degrade but their containers (cylinder valves, regulators) may limit shelf life

Distribution and Records

• § 213.150 — Warehousing and distribution: written procedures must include a lot traceability system allowing any distributed batch to be recalled rapidly; for medical gases, this means cylinder tracking (serial number, fill lot, ship-to location); batch traceability is essential for the FDA's medical gas recall system when contamination or mis-fill is discovered

• § 213.180 — Record availability: all records must be readily available for FDA inspection at the establishment; record retention must meet minimum periods (generally 1 year after expiration date, or 3 years after distribution if no expiration)

• § 213.196 — Distribution records: must record gas name, lot/batch number, consignee name and address, and date and quantity shipped; for mixed gas products (e.g., 50% oxygen/50% nitrous oxide blends, or specific CO₂/O₂ mixtures), the percentage of each component must be documented

• § 213.204 — Returned medical gases: returned gas cylinders must be held and evaluated for safety before reuse; cylinders that may have been stored or transported under adverse conditions (heat, contamination exposure) must not be refilled without determination that the container and gas meet specifications; contaminated cylinders must be destroyed or properly decontaminated

How It Affects You

If you manufacture or distribute medical gases: Part 213 compliance requires written QMS documentation across all operations — quality unit, equipment qualification, COA review, batch production records, label reconciliation, and distribution traceability. FDA inspects medical gas facilities under its drug GMP inspection program; observations under Part 213 appear on Form 483 and can escalate to Warning Letters. The highest-risk violations involve mix-up prevention failures: inadequate CGA fitting controls, label control failures, or insufficient in-process oxygen analysis. A cylinder of nitrogen labeled as oxygen constitutes an adulterated and misbranded drug, is immediately actionable, and can prompt a mandatory Class I recall.

If you operate a hospital, surgical center, or home care company receiving medical gases: your gas supplier must meet Part 213 standards. When a hospital selects a medical gas supplier, vendor qualification should include review of FDA inspection history (available at FDA's compliance database). For bulk liquid oxygen systems (common at hospitals), the Part 213 responsibilities for testing and documentation rest with the licensed gas manufacturer, not the hospital — but hospitals have their own Joint Commission and state health department obligations for medical gas system installation, pressure management, and alarm response.

If you prescribe or administer medical gases: the patient-safety framework depends on a functioning Part 213 supply chain. The CGA (Compressed Gas Association) pin-indexed valve connection system — where oxygen connectors (CGA 540) physically cannot mate with nitrogen connectors (CGA 580) — is the final physical barrier against gas mix-ups at the point of administration. This connection standard operates under CGA voluntary standards that are cross-referenced in Part 213 facility design requirements.

Statutory Authority

This rule implements:

• 21 U.S.C. § 351 — adulteration of drugs; a drug manufactured under conditions not conforming to GMP is adulterated
• 21 U.S.C. § 352 — misbranding of drugs; incorrect labeling, including gas identity errors, constitutes misbranding

Recent Rulemakings

Part 213 was established as a final rule on June 18, 2024 (89 FR 51746), with a primary effective date of December 18, 2025; companion amendments to Part 4 (combination products) are effective February 2, 2026. The rule was promulgated after years of FDA enforcement experience demonstrating that the general pharmaceutical GMP (21 CFR Parts 210–211) was inadequate to address gas-specific issues. FDA issued draft compliance guidance in December 2025 (90 FR 95-series, December 1, 2025).

Pending Action